These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 27931691)

  • 1. Risk assessment of hepatotoxicity among tuberculosis and human immunodeficiency virus/AIDS-coinfected patients under tuberculosis treatment.
    Ngouleun W; Biapa Nya PC; Pieme AC; Telefo PB
    Int J Mycobacteriol; 2016 Dec; 5(4):482-488. PubMed ID: 27931691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal Levels of Liver Enzymes and Hepatotoxicity in HIV-Positive, TB, and HIV/TB-Coinfected Patients on Treatment in Fako Division, Southwest Region of Cameroon.
    Enoh JE; Cho FN; Manfo FP; Ako SE; Akum EA
    Biomed Res Int; 2020; 2020():9631731. PubMed ID: 32462039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.
    Sekaggya-Wiltshire C; von Braun A; Scherrer AU; Manabe YC; Buzibye A; Muller D; Ledergerber B; Gutteck U; Corti N; Kambugu A; Byakika-Kibwika P; Lamorde M; Castelnuovo B; Fehr J; Kamya MR
    J Antimicrob Chemother; 2017 Apr; 72(4):1172-1177. PubMed ID: 28108678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia.
    Marzuki OA; Fauzi AR; Ayoub S; Kamarul Imran M
    Singapore Med J; 2008 Sep; 49(9):688-93. PubMed ID: 18830542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
    Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study.
    Wondwossen Abera ; Waqtola Cheneke ; Gemeda Abebe
    Int J Mycobacteriol; 2016 Mar; 5(1):14-20. PubMed ID: 26927985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antituberculosis drugs and hepatotoxicity among hospitalized patients in Jos, Nigeria.
    Isa SE; Ebonyi AO; Shehu NY; Idoko P; Anejo-Okopi JA; Simji G; Odesanya RU; Abah IO; Jimoh HO
    Int J Mycobacteriol; 2016 Mar; 5(1):21-6. PubMed ID: 26927986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor?
    Nader LA; de Mattos AA; Picon PD; Bassanesi SL; De Mattos AZ; Pineiro Rodriguez M
    Ann Hepatol; 2010; 9(1):70-4. PubMed ID: 20308724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of tuberculosis patients in the integrated tuberculosis control model in Chongqing, China: a retrospective study.
    Zhang L; Xing W; Zhou J; Zhang R; Cheng Y; Li J; Wang G; Liu S; Li Y
    BMC Infect Dis; 2020 Aug; 20(1):576. PubMed ID: 32758169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
    Jeong I; Park JS; Cho YJ; Yoon HI; Song J; Lee CT; Lee JH
    J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity.
    Singla R; Sharma SK; Mohan A; Makharia G; Sreenivas V; Jha B; Kumar S; Sarda P; Singh S
    Indian J Med Res; 2010 Jul; 132():81-6. PubMed ID: 20693595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatotoxicity during TB treatment in people with HIV/AIDS related to NAT2 polymorphisms in Pernambuco, Northeast Brazil.
    Araujo-Mariz C; Militão de Albuquerque MFP; Lopes EP; Ximenes RAA; Lacerda HR; Miranda-Filho DB; Lustosa-Martins BB; Pastor AFP; Acioli-Santos B
    Ann Hepatol; 2020; 19(2):153-160. PubMed ID: 31734174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced hepatotoxicity and association with slow acetylation variants NAT2*5 and NAT2*6 in Cameroonian patients with tuberculosis and HIV co-infection.
    Cho FN; Achidi EA; Enoh JE; Pallerla SR; Linh LTK; Tong HV; Kamgno J; Penlap VB; Adegnika AA; Lekana-Douki JB; Bouyou-Akotet MK; Kahunu GM; Lutete GT; Bates M; Tembo J; Elton L; McHugh TD; Grobusch MP; Zumla A; Ntoumi F; Velavan TP
    BMC Infect Dis; 2024 Jul; 24(1):759. PubMed ID: 39085767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence, drug-induced hepatotoxicity, and mortality among patients multi-infected with HIV, tuberculosis, and hepatitis virus.
    Mo P; Zhu Q; Teter C; Yang R; Deng L; Yan Y; Chen J; Zeng J; Gui XE
    Int J Infect Dis; 2014 Nov; 28():95-100. PubMed ID: 25218771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of TB/HIV co-infected patients presenting with antituberculosis drug-induced liver injury.
    Naidoo S; Evans D; Jong E; Mellet K; Berhanu R
    S Afr Med J; 2015 Apr; 105(5):393-6. PubMed ID: 26242667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral hepatitis prevalence in patients with active and latent tuberculosis.
    Nooredinvand HA; Connell DW; Asgheddi M; Abdullah M; O'Donoghue M; Campbell L; Wickremasinghe MI; Lalvani A; Kon OM; Khan SA
    World J Gastroenterol; 2015 Aug; 21(29):8920-6. PubMed ID: 26269682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B or hepatitis C co-infection in individuals infected with human immunodeficiency virus and effect of anti-tuberculosis drugs on liver function.
    Padmapriyadarsini C; Chandrabose J; Victor L; Hanna LE; Arunkumar N; Swaminathan S
    J Postgrad Med; 2006; 52(2):92-6. PubMed ID: 16679670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An official ATS statement: hepatotoxicity of antituberculosis therapy.
    Saukkonen JJ; Cohn DL; Jasmer RM; Schenker S; Jereb JA; Nolan CM; Peloquin CA; Gordin FM; Nunes D; Strader DB; Bernardo J; Venkataramanan R; Sterling TR;
    Am J Respir Crit Care Med; 2006 Oct; 174(8):935-52. PubMed ID: 17021358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen.
    Mankhatitham W; Lueangniyomkul A; Manosuthi W
    Southeast Asian J Trop Med Public Health; 2011 May; 42(3):651-8. PubMed ID: 21706943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review.
    Atwine D; Bonnet M; Taburet AM
    Br J Clin Pharmacol; 2018 Aug; 84(8):1641-1658. PubMed ID: 29624706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.